MORF-057 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 97 | 潰瘍性大腸炎 | 3 |
97. 潰瘍性大腸炎
臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05611671 (ClinicalTrials.gov) | October 31, 2022 | 31/10/2022 | A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC | A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-2) | Inflammatory Bowel Diseases;Colitis, Ulcerative | Drug: MORF-057;Drug: Placebo | Morphic Therapeutic, Inc | NULL | Recruiting | 18 Years | 85 Years | All | 280 | Phase 2 | United States;Australia |
| 2 | EUCTR2021-005288-31-PL (EUCTR) | 04/07/2022 | 19/05/2022 | A Phase 2a study to evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Ulcerative Colitis | A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis | Moderate to Severe Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: MORF-057 Product Code: MORF-057 INN or Proposed INN: MORF-057 Other descriptive name: MORF-057 | Morphic Therapeutic, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 35 | Phase 2 | United States;Poland | ||
| 3 | NCT05291689 (ClinicalTrials.gov) | May 24, 2022 | 10/3/2022 | A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC | A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1) | Inflammatory Bowel Diseases;Colitis, Ulcerative | Drug: MORF-057 | Morphic Therapeutic, Inc | NULL | Recruiting | 18 Years | 85 Years | All | 40 | Phase 2 | United States;Poland |